

## Gastroenterología y Hepatología



https://www.elsevier.es/gastroenterologia

## LONG-TERM PROGRAMMATIC PARTICIPATION PATTERNS, POSITIVITY RATES, AND YIELDS FOR NEOPLASIA IN CATALONIA'S ORGANIZED FECAL IMMUNOCHEMICAL (FIT)-BASED COLORECTAL CANCER (CRC) SCREENING PROGRAM

Uri Ladabaum<sup>1</sup>, Rebeca Font<sup>2</sup>, Josep A. Espinàs<sup>2</sup>, Xavier Castells<sup>3</sup>, Maria Pellisé<sup>4</sup>, Francesc Balaguer<sup>4</sup> and Antoni Castells<sup>4</sup>

<sup>1</sup>Gastrointestinal Cancer Prevention Program, Stanford University School of Medicine. <sup>2</sup>Oficina de Cribratge de Càncer, Pla Director d'Oncologia, L'Hospitalet de Llobregat. <sup>3</sup>Servicio de Epidemiología, Hospital del Mar, Barcelona. <sup>4</sup>Servicio de Gastroenterología, Hospital Clínic de Barcelona.

## Resumen

Introduction: The emergence of blood-based biomarkers intensifies the demand for data on the real-world long-term uptake and yield of FIT.

Objectives: To characterize long-term participation patterns, FIT positivity rates and yields for neoplasia in the Catalan FIT-based CRC screening program since 2010.

Methods: Participation, FIT positivity and yield (CRC; high-risk precursors = advanced adenoma/sessile serrated lesion or 5+ non-advanced ones) were determined with 2 perspectives: 1) Program (all persons regardless of age at entry); 2) Adherent cohort (entry at 50-51 yo with longitudinal consistent/frequent [100%/66-99% of rounds offered] participation).

Results: Participation patterns: Among 2.81M persons with 1-9 rounds offered/person, participation patterns were: 29.2% consistent, 8.6% frequent, 16.0% occasional [1-65%], and 46.2% never. FIT participation & positivity: Per-round FIT completed/offered ranged 39-60% for the Program, and 91-98% for the Adherent Cohort. FIT-positivity was highest in round 1 and settled at a steady state in rounds 2+ in both scenarios. Neoplasia yield: CRC/1,000 persons completing FIT was substantially higher in round 1 vs. rounds 2+ in both scenarios. Similarly, high-risk precursor and CRC detection were highest in round 1, with CRC detection settling at a steady state and high-risk precursor detection remaining substantial in rounds 2+. Adherent Cohort vs. Program: FIT-positivity and neoplasia yield were higher at a given round in the Program vs. Adherent cohort.

	Participation	and PIT positivity		Neoplasia yield at colonoscopy			S 107% Comprehe	veneive program data (all	persons, entry ag	1. 1	I vars	istent/hequent persopents ente
Round	Insted, n (median age)	FIT completed, n (% of invited)	Fill positive, n(% of completed)	CRCs, o (% affill- with catonoscopy)	High-marCRC precursor*, n(%-of FIS+with caleneacopy)	CRC detection rate per 1,000 participants completing FIT	4 20			22 22 24 2	im .	FT companie (% of invited) Colorador concer (vite per 1,800 pena companing FT)
		Comprehen	nive programmatic dat	a (all persons)			200	companie (t. 4' mobile)		S S S	100	\
346	2,807,160 (55.0)	1,065,954 (39%)	63,365 (5.8%)	2,874(5.1%)	11,475 (20%)	2.7	\$ 104 000	replacing P(T)		8	\$ 10%	-
2nd	2,153,501 (57.8y)	932,890 (43%)	96,317 (5.0%)	1,461(3.6%)	6,809(17%)	1.6				66		
310	1,640,636 (50:3y)	772,856 (47%)	33,091 (4.3%)	1,084 (3.7%)	3,572(32%)	1.4	No.	DER DE DE S	in on In		hel	
en	1,105,809 (61.2)	995,218 (50%)	24,812 (4.9%)	709(3.4%)	2,098 (30%)	1.3					(90.2	U DENI DANI DANI DANI DANI D
505	294,455 (62.3y)	160,331 (16%)	7,105 (4.4%)	217(3.8%)	729 (13%)	1.4		cowing rund shoot (necls	on age in years)			Sciencing round offered (median age
601	139(676 (63.5y)	77,562(56%)	3,132 (4.0%)	96 (3.7%)	267(50%)	1.3						
700	61,574(64,71)	36,902 (80%)	1,671 (4.5%)	29(2.2%)	94(7%)	0.8	Comprehe	ensive program data (all	persons, erroy age	m)	Conv	intert/frequent participants enter
BOh:	1,654 (65.0)	880 (54%)	41(4.6%)	0(0%)	2(7%)	0.0	11	wild proline	(% of completed)	1	2 20%	will positive (% of
901	13 (94.9)	5(39%)	1(20%)	0(0%)	0 (0%)	0.0	11 =		anner (h. amera)		30h	
			pert participants with				8 8 8 8	10 common	more (5 arrang	1	19555	PT violannesses)
14	400,179 (90.2)	364,360 (91%)	16,040 (4,4%)	474(3.3%)	1,909 (13%)	1.30	11 m			1 7	12 00	1
214	288,131 (52.3)	269,851 (94%)	8,547 (3.0%)	134(1.9%)	560 (8%)	0.50	el min		.0	1		0-0
3rd	298,302 (54.4)	195,247 (93%)	6,496 (3.3%)	104(1.8%)	409 (7%)	6.53	11 0			1 1		
4h	135,452 (56.4)	109,874 (94%)	3,590 (3.2%)	50(3.6%)	212(7%)	0.46	11 0				n :	
Sith	41,660 (58.4)	39,744 (95%)	1,254(3.2%)	27(2.5%)	95 (9%)	0.68	2 -				2 Ph	
601	21,761,960,360	20,435 (94%)	683 (3.7%)	\$7(2.0%)	44(8%)	0.63	Ph 14	2nd 3nd 4th 1	n		69	
76h	8,939 (92.5g) 137 (63.3e)	8,479 (95%)	312(3.7%)	4(1.6%)	8 (2%)	6.47	(55.40)	STAL SAN STALLS	DAY BONG BAN		- 1	E DIE DIE 48 SE DI DENI DENI DENI DENI
BO:		534 (96%)	4(3.0%)	010961	0.10%)							

Conclusions: With current program design, 46% of eligible persons do not participate, and among participants, 70% are consistent/frequent. Yield is highest at round 1, as expected due to detection of prevalent neoplasia, but yield at rounds 2+ remains substantial. The Program vs. Adherent cohort results across rounds with similar ages suggest that consistent/frequent participation may decrease CRC incidence, presumably by removal of CRC precursors.